India’s Contract Development and Manufacturing Organisation sector has evolved into one of the most strategically important segments of the global pharmaceutical supply chain, with the Indian CDMO market valued at USD 25.51 billion in 2025 and expected to grow at a CAGR of 10.80 percent to reach USD 71.14 billion by 2035. India hosts more than 350 USFDA-registered pharmaceutical manufacturing facilities — one of the largest numbers outside the United States and Europe — and outsourcing pharmaceutical production to India reduces manufacturing costs by 30 to 40 percent compared to Western facilities. India produces over 200,000 life science graduates annually supporting R&D and manufacturing operations. In November 2025, Syngene International opened a new biologics manufacturing facility in Bangalore designed to meet USFDA standards for monoclonal antibody production, while Piramal Pharma Solutions announced a capacity expansion for high-potency APIs targeting the oncology market in September 2025. The China-plus-one global supply chain shift is creating new outsourcing opportunities for Indian CDMOs. Let us have a look at the top 10 CDMO companies in India for the year 2026.
1. Divi’s Laboratories Limited
Divi’s Laboratories, founded in the year 1990 by Dr. Murali Krishna Prasad Divi and headquartered in Hyderabad, is one of the world’s most trusted Active Pharmaceutical Ingredient producers and India’s leading CDMO for custom synthesis serving the world’s largest global pharmaceutical innovators. The company operates world-class manufacturing facilities in Hyderabad and Visakhapatnam that fully meet global standards including USFDA, WHO, and EU-GMP, and is known for its quality, reliability, and long-term client partnerships with the world’s largest pharmaceutical companies. A new facility is being constructed in Kakinada, Andhra Pradesh to support growing custom synthesis demand.
Divi’s Laboratories serves the world’s largest pharmaceutical innovators with its custom synthesis capabilities for complex API and intermediate manufacturing, and is the top choice of global pharma companies for their most sensitive and proprietary drug substance manufacturing given its combination of technical excellence, regulatory compliance, and decades-long trust-based partnerships.
2. Syngene International Limited
Syngene International, established in the year 1993 as a part of Biocon Group and headquartered in Bengaluru, is a true end-to-end Contract Research, Development, and Manufacturing Organisation offering integrated services from drug discovery through commercial-scale production spanning small molecules, biologics, and animal health. The company opened a new USFDA-standard biologics manufacturing facility for monoclonal antibody production in Bangalore in November 2025, and is expanding into ADC development, oligonucleotides, protein sciences, DMPK, and toxicology capabilities. Its client base includes global pharma giants Bristol-Myers Squibb, GSK, and Amgen.
Syngene serves global pharmaceutical and biotechnology companies with its comprehensive drug development and manufacturing services, and is India’s most fully integrated CRDMO whose ability to serve clients from early discovery through commercial manufacturing under a single-company relationship is a distinctive competitive advantage that differentiates it from CDMOs focused only on manufacturing.
3. Piramal Pharma Solutions
Piramal Pharma Solutions, the CDMO division of Piramal Pharma Limited established in the year 1988 and headquartered in Mumbai, is a globally recognised CDMO with one of the most comprehensive service portfolios in the industry including high-potency APIs, antibody-drug conjugates, sterile injectables, formulation development, and clinical trial supply manufacturing. In September 2025, Piramal Pharma Solutions announced a capacity expansion for high-potency APIs targeting the oncology market, where specialised containment handling is required, supporting the global supply chain for cancer medications. The company operates facilities across North America, Europe, and India.
Piramal Pharma Solutions serves global pharmaceutical companies developing innovative oncology, rare disease, and specialty molecule drugs with its specialised high-potency API and injectable manufacturing capabilities that require Level 5 containment infrastructure not widely available among global CDMOs.
4. Sai Life Sciences Limited
Sai Life Sciences, founded in the year 1999 and headquartered in Hyderabad, is a leading integrated Contract Research and Manufacturing Organisation providing services spanning drug discovery chemistry, process development, and commercial manufacturing for global pharmaceutical and biotech innovator companies. The company is a favourite among Western biotech companies for small molecule drug development outsourcing and has built a strong reputation for scientific excellence combined with reliable delivery against development milestones.
Sai Life Sciences serves global pharmaceutical innovators and biotech companies seeking integrated drug development and manufacturing partners with its end-to-end small molecule CRMO capabilities, and is particularly well-regarded by US and European biotech companies for its combination of scientific quality, transparency, and efficient milestone delivery.
5. Laurus Labs Limited
Laurus Labs, established in the year 2005 and headquartered in Hyderabad, is a leading API manufacturer and CDMO with strong capabilities in antiretroviral APIs, oncology molecules, and formulation development for small-molecule pharmaceuticals. The company provides API manufacturing, formulation development, and CDMO services for pharmaceutical companies globally and has been expanding rapidly by investing in new capacities across synthesis, bioprocessing, and fermentation. Laurus Labs is cited among the top CDMO companies in India for its specialisation in high-volume, cost-competitive API manufacturing for global markets.
Laurus Labs serves global pharmaceutical companies requiring cost-competitive large-volume API manufacturing for antiretroviral, oncology, and other therapeutic area drugs, and is particularly important to global access to affordable HIV treatment medications given its significant production of antiretroviral APIs supplied to generic manufacturers serving developing markets.
6. Aragen Life Sciences (Formerly GVK Bio)
Aragen Life Sciences, formerly known as GVK Biosciences and headquartered in Hyderabad, is one of India’s most established contract research and development organisations offering drug discovery, development, and manufacturing services to global pharmaceutical and biotech companies. The company has rebranded from GVK Bio to Aragen Life Sciences as part of strategic repositioning and serves clients from lead identification through commercial manufacturing with integrated chemistry, biology, and manufacturing capabilities.
Aragen Life Sciences serves global drug innovators with its integrated drug discovery and development capabilities spanning chemistry, biology, and manufacturing services, and is one of India’s longest-established CRO-to-CDMO companies whose track record of serving global pharmaceutical clients since the early 2000s gives it deep insight into the operational and quality standards that international pharmaceutical companies require.
7. Jubilant Pharmova Limited
Jubilant Pharmova, the pharmaceutical services division of the Jubilant Bhartia Group headquartered in Noida, is a leading CRDMO offering integrated discovery research, API manufacturing, formulation development, and sterile injectable production services. The company’s CDMO business serves global pharmaceutical companies with complex drug substance and drug product manufacturing capabilities, and Cipla’s October 2025 strategic investment in mRNA technology demonstrates how established pharmaceutical companies are investing in next-generation manufacturing capabilities.
Jubilant Pharmova serves global pharmaceutical innovators with its integrated CDMO capabilities spanning radiopharmaceuticals, sterile injectables, and allergy therapy products, and is one of India’s most diversified pharmaceutical services companies with capabilities in both drug substance and drug product manufacturing across multiple dosage forms and complexity levels.
8. Neuland Laboratories Limited
Neuland Laboratories, a publicly listed CDMO headquartered in Hyderabad, is a leading API manufacturer and CDMO specialising in complex, niche molecules and peptides where its technical capabilities in handling complex chemistry create meaningful competitive barriers. The company is a key API manufacturer and CDMO partner for pharmaceutical innovators seeking suppliers with deep expertise in challenging synthesis routes, asymmetric chemistry, and peptide manufacturing that require specialised process development expertise.
Neuland Laboratories serves pharmaceutical companies requiring complex API manufacturing expertise for niche therapeutic molecules and peptides, and its specialisation in technically challenging chemistry creates a defensible competitive position compared to commodity API manufacturers competing primarily on price for simpler molecule manufacturing.
9. Aurobindo Pharma Limited (CDMO Division)
Aurobindo Pharma, established in the year 1986 and headquartered in Hyderabad as one of India’s major generic pharmaceutical companies with presence across 125 countries, has been building its CDMO capabilities alongside its core generics business. Aurobindo’s acquisition of Lannett Company in the USA gave it a US-based manufacturing facility and a CDMO business specialised in controlled substances, adding a new dimension to its CDMO offerings that complements its extensive API and formulation manufacturing capabilities across both India and international facilities.
Aurobindo Pharma serves global pharmaceutical companies with its extensive API and formulation CDMO capabilities across a large network of USFDA and EMA-compliant manufacturing facilities, and its controlled substances CDMO capability acquired through Lannett addresses a specialised segment where regulatory expertise and DEA scheduling compliance are critical barriers to entry.
10. Suven Pharmaceuticals Limited
Suven Pharmaceuticals, a publicly listed company headquartered in Hyderabad, is cited among the top CDMO companies in India by multiple analyst assessments and specialises in providing CDMO services for complex intermediates and APIs with a focus on innovation-led chemistry for specialty pharmaceutical applications. The company maintains long-term client relationships with global pharmaceutical innovators and has built its CDMO business on scientific excellence and reliable delivery for technically challenging molecules.
Suven Pharmaceuticals serves global pharmaceutical innovators seeking complex chemistry CDMO services with long-term partnerships built on scientific reliability and regulatory compliance, and is one of India’s better positioned mid-size CDMOs for complex molecule manufacturing whose specialisation in technically demanding synthesis routes differentiates it from larger volume-focused competitors.
Frequently Asked Questions (FAQs)
Q: What is a CDMO and why is India becoming a global hub?
A: A CDMO or Contract Development and Manufacturing Organisation provides integrated pharmaceutical services including drug development, process optimisation, analytical testing, scale-up, GMP manufacturing, and regulatory support to pharmaceutical companies that prefer to outsource rather than build their own manufacturing infrastructure. India is becoming a global CDMO hub due to its 350 plus USFDA-registered facilities, 30 to 40 percent cost advantage over Western manufacturers, 200,000 plus annual life science graduates, and strong regulatory compliance track record.
Q: What is the size of India’s CDMO market in 2026?
A: The Indian CDMO market was valued at USD 25.51 billion in 2025 and is expected to grow at a CAGR of 10.80 percent to reach USD 71.14 billion by 2035. The broader Indian pharmaceutical outsourcing market is expected to surpass USD 30 billion, driven by increasing outsourcing of APIs, biologics, peptides, and specialty formulations as global pharmaceutical companies seek cost-efficient and quality-compliant manufacturing partners.
Q: Which are the top CDMO companies in India?
A: Divi’s Laboratories, Syngene International, and Piramal Pharma Solutions are consistently cited as the top three CDMO companies in India. Sai Life Sciences, Laurus Labs, and Aragen Life Sciences round out the next tier. For biologics CDMO, Syngene and Piramal Pharma Solutions lead with their monoclonal antibody and high-potency injectable manufacturing capabilities. For small molecule API custom synthesis, Divi’s Laboratories is the most globally recognised.
Q: How is the China-plus-one trend affecting Indian CDMOs?
A: The China-plus-one global pharmaceutical supply chain diversification trend is creating significant new business opportunities for Indian CDMOs as pharmaceutical companies reduce their dependence on Chinese API and drug product manufacturing. India is the natural beneficiary given its existing regulatory infrastructure, English-speaking scientific workforce, and established track record with global pharmaceutical companies. Indian CDMOs are investing in capacity expansion and new therapeutic area capabilities to capture this structural opportunity.
Q: What is the difference between a CRO, CDMO, and CMO?
A: A CRO or Contract Research Organisation focuses on research services like drug discovery and preclinical and clinical testing without manufacturing. A CMO or Contract Manufacturing Organisation provides manufacturing services without drug development capabilities. A CDMO or Contract Development and Manufacturing Organisation provides the integrated combination of both development and manufacturing services under a single contract, allowing pharmaceutical clients to transition from early development to commercial production without changing service partners. Indian companies like Syngene and Piramal Pharma Solutions are true CDMOs while some companies are primarily CMOs or CROs.
